IE 11 is not supported. For an optimal experience visit our site on another browser.

NovaBay Pharmaceuticals to Present at Rodman and Renshaw Annual Global Investment Conference

/ Source: GlobeNewswire

EMERYVILLE, Calif., Sept. 7, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds (NYSE Amex:NBY), announces that Thomas Paulson, CFO, will present at the Rodman & Renshaw Annual Global Investment Conference. The presentation is currently scheduled for 12:05 PM, September 14, 2010, in the Fahnestock Salon, 5th Floor of the New York Palace Hotel in New York City.

This audio presentation with slides will be available via webcast at:

Under a collaboration agreement with Alcon Manufacturing Ltd. (NYSE:ACL), the two companies are developing NovaBay's Aganocide compounds for the treatment of eye, ear and sinus infections, as well as for the care of contact lenses. NovaBay has also partnered with Galderma S.A., for the development of NovaBay's Aganocide compounds for major dermatologic conditions.

Recently, NovaBay reported positive results of a Phase 2a trial of NVC-422 for the treatment of impetigo, which demonstrated that the company's lead drug candidate was safe and efficacious against impetigo, including cases caused by methicillin-resistant Staph. aureus. NovaBay also reported positive results from an open label exploratory Phase 2a trial of the company's lead Aganocide compound, NVC-422, for the treatment of bacteriuria, or bacteria in the urine, in chronically catheterized patients. The study showed that NVC-422 was well-tolerated and that it reduced or eliminated certain pathogens in the urine.

In addition, NovaBay received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent is expected to broaden protection for NovaBay's first-in-class Aganocide family of compounds, and will cover compositions of matter and methods of use for NVC-612 and related compounds.

Following the live presentation, an audio and slide archive of the presentation will be available under the "Events" page in the "News & Events" section of the Company's website at

To request a one-on-one meeting or to be added to NovaBay's email list, please contact Adam Holdsworth at or call 212-825-3210.

About Rodman & Renshaw

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005.

About Aganocide Compounds

The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay to mimic the body's natural defense against infection. The Aganocide compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated, first-in-class, small-molecule chemical entities, including NovaBay's patented lead compound NVC-422, may be able to deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide compounds have been shown to be highly effective against bacteria, including multi-drug resistant strains, viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a high therapeutic index while providing a high degree of potency and tolerability as well as dosing versatility and flexibility.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic, anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing dermatological, hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. For more information on NovaBay, visit:

CONTACT: NovaBay Pharmaceuticals, Inc. Investors: Thomas J. Paulson, Chief Financial Officer 510-899-8809 The Investor Relations Group Investor Relations Adam Holdsworth 212-825-3210 Public Relations Laura Colontrelle 212-825-3210